Introduction
The endocannabinoid system (ECS) plays a central role in the regulation of a number of physiological processes in the human body, including mood, appetite, pain, memory formation, and the immune response. 1, 2 Therefore, modulation of the ECS has been increasingly explored for therapeutic intervention in human health and disease. 3, 4 Included among the biomolecular constituents of the ECS are the cannabinoid receptors CB 1 and CB 2 , which belong to the guanine nucleotide binding protein (G protein)-coupled receptor (GPCR) superfamily of proteins, and couple to G i/o , which inhibits the intracellular accumulation of the second messenger, cyclic adenosine monophosphate (cAMP). 5 Due to the diverse roles of the ECS and the success of targeting GPCRs in drug development, 6 the cannabinoid receptors are encouraging yet underexplored targets in the discovery of novel pharmacotherapies.
Currently marketed drugs that target the cannabinoid receptors include Cesamet (nabilone), Marinol [dronabinol/Δ 9 contains a number of pharmacologically active compounds, including Δ 9 -THC, and elicits feelings of relaxation and analgesia. 7, 8 Although Δ 9 -THC and other cannabinoids are promising in their therapeutic effects, unfortunately, a number of negative side effects are also associated with their use, including depression, tolerance, and dependence. 2, 9 Although Δ 9 -THC and the aforementioned drugs are known to bind to CB 1 and CB 2 receptors, 10 the psychoactive side effects have largely been associated with modulation of the CB 1 receptor expressed in neurons throughout the CNS. 11, 12 As a consequence, drugs that solely target the CB 2 receptor, achieved by developing CB 2 -selective scaffolds, may abrogate these negative side effects 12, 13 and are attractive for future ECS modulation.
The CB 2 receptors, unlike the CB 1 subtype, are largely expressed peripherally in cells of the immune system, 1, 5 although they are also distributed in the CNS, primarily in microglia. 5, 14 Due to their unique expression pattern, drug discovery efforts targeting the CB 2 receptor have largely been focused on the treatment of pain and inflammation, although utility for other indications is also possible. 15 For example, CB 2 expression is increased by inflammatory stimuli, 16 and neuropathological findings in human brains suggest that upregulation of CB 2 is a common response to chronic injury, and may play an important role in diseaseassociated neuroinflammation 17 and the inhibition of glial cell tumors. 18 For instance, CB 2 receptors are upregulated in microglial cells located in the periphery of senile plaques of people with Alzheimer's disease and in the striatum of a rat model of Huntington's disease. In microglia, this upregulation is thought to control the production of neurotoxic factors, including nitric oxide, proinflammatory cytokines, and reactive oxygen species. Furthermore, cannabinoid receptor knockout mice reveal that analgesia is likely mediated by CB 2 and not by CB 1 . 19, 20 Thus, identification of compounds that activate the CB 2 receptor to the exclusion of the CB 1 receptor may promote analgesia and modulate the body's response to inflammation, without the psychoactive side effects associated with CB 1 activation.
Because CB 1 and CB 2 receptor subtypes share sequence homology (~44% overall similarity, ~68% within the transmembrane regions), 21, 22 identification of ligands with a high degree of selectivity for CB 2 versus CB 1 has proven challenging. 22 One emerging approach for improving selectivity is the discovery and development of allosteric modulators. 23 Allosteric modulators are compounds that bind to an allosteric site that is topographically distinct from the binding site of the endogenous ligands (the orthosteric site). Allosteric binding sites are often less evolutionarily conserved than orthosteric sites, providing greater opportunity for small molecules to exhibit selectivity between receptor subtypes, as well as providing other potential therapeutic advantages over traditional orthosteric agonists. 24 Although positive allosteric modulators (PAMs) of the CB 1 receptor have previously been identified, [25] [26] [27] [28] [29] there are no known CB 2 allosteric modulators. Structural modeling of the CB 2 receptor, however, suggests the existence of an allosteric binding pocket adjacent to the orthosteric site, 30 supporting the idea that it may be possible to discover CB 2 PAMs.
Here, we performed a high-throughput screening (HTS) of a 60,000-compound library in mammalian cells to identify agonists or PAMs of the CB 2 receptor. Identification of potent, CB 2 -selective compounds will not only contribute to the pharmacological toolkit available to probe the physiological role of the cannabinoid receptors, but also provide potential starting points for the development of novel drugs to treat pain and inflammation without the psychoactive side effects associated with CB 1 drugs.
Materials and Methods

High-Throughput Screening
The HTS was performed using a collaboration deck that consisted of approximately 60,000 commercially available compounds arranged in 1536-well Echo Qualified source plates (Labcyte, Sunnyvale, CA). Each compound was dissolved in DMSO at a concentration of 3 mM. Compounds were then transferred to white, tissue culture-treated, 1536-well assay plates (3727BC; Corning, Corning, NY) by acoustic dispense using an Echo-550 (Labcyte) to yield a final concentration of 15 µM in the screening assay. Two separate screens were performed, and each of the 60,000 compounds were tested a single time in each of the two screens. To discover any PAMs present in the compound set, screening was performed in the presence of the CB 2 orthosteric agonist CP 55,940 (Sigma-Aldrich, St. Louis, MO). CP 55,940 was dissolved in DMSO and transferred to the assay plates by acoustic dispense. In Screen 1, we used an approximate EC 10 concentration of CP 55,940 that was determined by testing the compound in a 10-point concentration-response curve using an assay measuring the inhibition of cAMP accumulation, described herein (30 pM; Suppl. Fig. 1) . In Screen 2, we used an EC 25 concentration of CP 55,940 (50 pM; Suppl. Fig. 1 ). Both the screening compounds and CP 55,940 were added prior to HTS assay initiation.
Cryopreserved Chinese hamster ovary (CHO-K1) cells expressing recombinant human CB 2 receptors (CHO-K1-CB 2 ) were then added to the assay plates to yield 500 cells per well. Prior to cryopreservation, cells were grown to confluence in F-12 media supplemented with 10% fetal bovine serum (FBS), 100 IU/mL penicillin, 100 µg/mL streptomycin, and 250 µg/mL G418, in T-175 tissue culture flasks, and harvested with TrypLE Express. For use in the screens, cells were thawed, washed in F-12 media with 1% FBS, and then resuspended in assay buffer before being added to the assay plates. The assay buffer was Hanks Balanced Salt Solution (HBSS) with calcium and magnesium supplemented with 25 mM HEPES, 100 IU/mL penicillin, 100 µg/mL streptomycin, and 0.05% bovine serum albumin (BSA; Sigma-Aldrich). All media and supplements were purchased from Life Technologies (Carlsbad, CA) unless otherwise indicated.
Finally, forskolin (Sigma-Aldrich) was added to the assay plates (5 µM final concentration) to stimulate adenylyl cyclase activity. Forskolin was dissolved in DMSO and diluted in assay buffer. The final concentration of DMSO in the assay was 0.67%. Assay plates were then incubated for 45 min at room temperature, followed by lysis and cAMP detection. Unlike many other cAMP accumulation assays, the inhibition of the forskolin-stimulated cAMP window in CHO-K1-CB 2 cells was more robust in the absence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), so IBMX was not added to the assay conditions.
As a positive control, each assay plate contained two columns that were treated with a maximally effective concentration of CP 55,940 (33 nM; Suppl. Fig. 1 ) to define maximal (100%) inhibition of forskolin-stimulated cAMP accumulation. As a negative control, each assay plate also contained two columns that were not treated with CP 55,940 (DMSO alone) to define control levels (0% inhibition) of forskolin-stimulated cAMP accumulation.
Hit Assessment
Concentration-Response Curves. Ten-point concentrationresponse curves were performed for hits in both the presence (PAM mode) and absence (agonist mode) of CP 55,940, and in CHO-K1 cells lacking the expression of the CB 2 receptor (null mode). Compounds were serially diluted in DMSO, with threefold dilutions between concentrations, ranging from 20 µM to 1 nM, and then transferred by acoustic dispense into 1536-well assay plates. For PAM mode, concentration-response curves were performed as in the primary screens. For agonist mode, the addition of the EC 10 concentration of CP 55,940 was replaced with DMSO. For null mode, agonist mode was performed in CHO-K1 rather than CHO-K1-CB 2 cells, and the positive control was assay buffer without forskolin because a maximally effective concentration of CP 55,940 was not expected to produce a response in the parental cells.
Each concentration-response curve was performed in triplicate. Concentration-response data were plotted as percentage inhibition of forskolin-stimulated cAMP accumulation and fit to a logistic equation using nonlinear regression analysis to provide estimates of E max (top) and potency (EC 50 ) in GraphPad Prism 7 [log(agonist) versus response (three parameters)]; bottom is constrained at 0, as defined by vehicle control wells (GraphPad Software, La Jolla, CA).
Inhibition of cAMP Accumulation Assay.
To test for CB 2 receptor activation, we measured inhibition of forskolin-stimulated cAMP accumulation. Assay plates with test compounds, forskolin, and cells were incubated at room temperature for 45 min, and reactions were terminated by the sequential addition of Eu-cAMP and ULight reagents from the LANCE Ultra cAMP Detection Kit (PerkinElmer, Cambridge, MA) in a 1:1 ratio. Following a 1 h incubation at room temperature, time-resolved fluorescence resonance energy transfer (TR-FRET) was measured on an Envision plate reader (PerkinElmer) with excitation at 337 nm and emission reads at 615 nm and 665 nm. The ratiometric data [(665 nm read / 615 nm read) × 10,000] were then converted to [cAMP] based on a standard curve for cAMP run at the same time and under identical conditions to the assay.
Radioligand Binding Assay. To determine the binding affinity of test compounds for cannabinoid receptors, human embryonic kidney (HEK293) cells were transfected with plasmid DNA encoding the human CB 1 or human CB 2 receptor, and 24 h posttransfection membranes were prepared as described previously. 31 Ligand binding was also determined essentially as described previously. 31, 32 In brief, nine different concentrations of the test compounds (from 100 pM to 100 µM) were incubated with cell membranes and the tracer [ 3 H]CP 55,940 (150.2 Ci/mmol; PerkinElmer) at 1.5 nM to achieve a robust signal while staying lower than the K D determined for this system. 33 Nonspecific binding was determined using 1 µM unlabeled CP 55,940. Experiments were performed in duplicate three times, and only two times when no binding was detected. 32 Experiments were performed in duplicate three times.
GTPγS Binding
Results
HTS Identifies CB 2 Agonists
To identify agonists or PAMs of the CB 2 receptor, a collaboration deck consisting of approximately 60,000 commercially available compounds was screened by the Lead Discovery group at Bristol-Myers Squibb (BMS) in collaboration with Yale University through its Educational Alliance program. We screened compounds in CHO-K1 cells expressing the human CB 2 receptor for inhibition of forskolin-stimulated increases in cellular cAMP levels in the presence of a low (EC 10 ) concentration (30 pM; Suppl. Fig. 1 ) of the orthosteric agonist CP 55,940. Screening in the presence of an orthosteric agonist enables detection of both agonists and PAMs in a single screen. Conditions were chosen based on assay optimization experiments, which included testing fresh versus cryopreserved cells, various cell-seeding densities, and varying concentrations of forskolin (1-20 µM). Once optimized, the screening run was completed in a single day, in workstation mode (40 × 1536-well plates). Despite assay optimization efforts, assay robustness for this screen was less than ideal, with a Z' median of 0.45 (±0.09) and a signal-to-background ratio (S:B) of 3.2, as defined by a maximally active concentration of CP 55,940 (33 nM; Fig. 1) .
Because weak (low-cooperativity) PAMs exhibit greater activity as the concentration of an orthosteric agonist is increased, 24, 34 to enhance our chances of identifying PAMs of the CB 2 receptor, we repeated the HTS using a higher EC 25 (50 pM; Suppl. Fig. 1 ) concentration of CP 55,940. As the concentration of the orthosteric agonist is increased, however, the "noise" (or scatter) associated with the assay is also typically increased. 24 Thus, as expected, the higher concentration of CP 55,940 further reduced assay robustness, resulting in a Z' median of 0.35 (±0.12) and S:B of 2.5 ( Fig. 1) . In addition, these screening conditions revealed a number of spurious false positives (cluster of compounds in the top left corner and lower right corner of Fig. 1 ) that did not validate after further testing. Nonetheless, combining the results of these two screens provided two data points for each of the 60,000 test compounds, thereby increasing the chances of identifying any PAMs or agonists that may have been present in the compound set. "Hits" were defined as the top 1% of compounds, which corresponded to compounds that produced ≥37% inhibition of cAMP accumulation relative to the maximal inhibition produced by CP 55,940 in either screen. This cutoff yielded 678 hits.
Hit Characterization in cAMP Accumulation Assay
The activities of hits were then validated in 10-point concentration-response curves (ranging from 1 nM to 20 µM) in both the presence (PAM mode) and absence (agonist mode) of CP 55,940 to distinguish potential PAM hits from direct agonists. Compounds active in PAM mode but inactive or significantly less potent in agonist mode would be considered putative PAMs, whereas agonists would be active in both modes. Hits were also tested in parental CHO-K1 cells lacking the expression of the CB 2 receptor (null mode) to confirm that observed effects on cAMP accumulation were CB 2 mediated. Hits active in null mode are likely producing their effects through "off-target," non-CB 2 -mediated mechanisms and were therefore excluded from further testing. Because only a small fraction of compounds elicited a response in null mode, for these compounds we compared potency and efficacy values among assays to determine whether the response was CB 2 mediated or nonselective. Of the 678 initial hits, 167 validated in the 10-point concentration-response curves and were CB 2 mediated (devoid of activity in null mode; Suppl. Fig. 2 ). All validated hits showed similar activity in both PAM and agonist modes (potency range: ~1 nM to >30 µM), suggesting that all of the compounds identified in our screen were direct CB 2 agonists, with no PAMs being identified. Of the 167 active compounds identified, 47 displayed a potency greater than 100 nM (EC 50 < 100 nM) in the cAMP accumulation assay. From these 47 hits, 4 compounds were initially selected for follow-up characterization based on a number of considerations, including observed potency in initial cAMP experiments as well as logistical factors such as compound availability. Concentrationresponse curves for select validated CB 2 agonists (Table 1) , and their structures, are depicted in Figure 2 , and their EC 50 and E max values provided in Table 2 . Future efforts will include the characterization of the remaining hits, including structure-activity relationship (SAR) studies. 
Radioligand Binding Reveals CB 2 -Selective Agonists
The selected CB 2 agonists were further characterized using a radioligand binding assay to determine their affinities for CB 1 
Characterization of Selected Hits Using a [
S] GTPγS Binding Assay
The CB 2 receptor couples to G proteins, predominantly the adenylyl cyclase inhibitory G proteins Gα i/o. Therefore, agonist-stimulated binding of [ 35 S]GTPγS was used to characterize agonist potency in a direct measure of receptor/G protein activation. 35 Cell membranes prepared from HEK293 cells expressing the CB 2 receptor were incubated with [
35 S]GTPγS and varying concentrations of each compound. The EC 50 values for Compounds 1-4 were 0.5 µM, log EC 50 : −6.3 (95% CI: −7.0, −5.6); 0.6 µM, log EC 50 : −6.3 (95% CI: −6.9, −5.6); 0.03 µM, log EC 50 : −7.4 (95% CI: −8.2, −6.5); and 0.08 µM, log EC 50 : −7.1 (95% CI: −7.5, −6.7), respectively ( Table 4) .
Discussion
In this study, we aimed to identify compounds with selectivity for CB 2 versus CB 1 receptors. The identification of allosteric modulators is one strategy for attaining selectivity, because allosteric ligands can sometimes exhibit superior selectivity between related receptor subtypes compared to orthosteric ligands, which bind to a site that is often more evolutionarily conserved. 24 We therefore performed a HTS of approximately 60,000 compounds in the presence of the orthosteric agonist CP 55,940, to allow the identification of agonists and PAMs of CB 2 . However, the two screens of the 60,000 compounds that were performed, differing only in the concentration of CP 55,940 (EC 10 and EC 25 ), did not reveal PAMs. Given that PAMs have previously been identified for the CB 1 receptor, these results were somewhat surprising. There are several possible explanations for the lack of PAM hits -one is that, despite structural modeling that suggests otherwise, 30 "druggable" allosteric sites simply may not exist on CB 2 .
There are, however, many other potential explanations for the lack of PAM hits from this screening effort. As discussed above, the assay robustness for this HTS campaign was less than ideal, and therefore it is possible that weak PAM hits may have been obscured by the relatively high noise level in the assay. It is also possible that our results were limited by the screening conditions we used and that screening using a different assay to detect G protein-dependent signaling, 36 or an alternative signaling pathway, 37, 38 would reveal PAMs. For instance, a label-free technology, such as a cell-impedancebased assay, has been used to evaluate CB 2 agonists, including the selective JWH133. 36 This avoided use of markers or dyes for detection, which were used here for detection of cAMP changes. Furthermore, the cannabinoid receptors display a range of signaling bias, or the ligand-dependent differential activation of one signaling cascade over another. Cannabinoid ligands have been documented to harbor β-arrestin bias as well as G protein bias, including bias among the various G proteins. [39] [40] [41] Allosteric modulators of the cannabinoid receptors, too, have been shown to elicit biased responses. 42, 43 For example, the allosteric modulator ORG27569 inhibits G protein coupling, while activating β-arrestin-2-mediated receptor internalization and β-arrestin-1-mediated ERK1/2 signaling. 42, 43 Furthermore, CB 1 PAMs at this point have largely been shown to potentiate β-arrestin signaling rather than G protein signaling. 25 Thus, although our screen focused on the identification of allosteric modulators that potentiate G protein signaling, screening compounds with an assay to detect changes in β-arrestin activity, like the PathHunter β-galactosidase fragment complementation assay (DiscoverX Corporation, Fremont, CA), which has been validated with the CB 1 receptor for HTS campaigns, 37 may be more likely to lead to the discovery of CB 2 PAMs. Because CB 2 typically undergoes desensitization and internalization after activation, an assay that is independent of the coupling partner's composition may be warranted. 37 Another factor to consider is that, due to technical considerations, the current screens were run using the synthetic agonist CP 55,940 as the orthosteric agonist, rather than a more physiologically relevant endocannabinoid. PAMs for CB 1 have been identified using CP 55,940 as the orthosteric agonist probe. Nonetheless, because of the phenomenon of "probe dependence" that allosteric modulators can exhibit, 24 we could have success identifying PAMs for CB 2 screening with a different orthosteric agonist (e.g., 2-AG or anandamide).
A more trivial explanation is that PAMs of CB 2 -mediated cAMP inhibition may exist but were not present in the compound collection that was screened. The current screens used a relatively small deck of 60,000 commercially available compounds that, although diverse, may simply not have contained any compounds that are PAMs for CB 2 . Therefore, we cannot conclude that PAMs of CB 2 do not exist simply because none were identified from the current HTS. Nonetheless, the fact that hundreds of CB 2 agonists were identified from this screen suggests that PAMs of CB 2 may be rarer than orthosteric agonists.
The screens did reveal a number of CB 2 agonists, 47 of which had a potency of greater than 100 nM (EC 50 < 100 nM), a relatively large number of high-potency hits from a screen of this size. Of these novel agonists, four selected for further characterization (Compounds 1-4 ) also displayed efficient G protein activation based on GTPγS binding data, validating the cAMP accumulation results. The potencies obtained in the cAMP accumulation assay were, however, somewhat different from those obtained in the GTPγS binding assay. Compounds 1 and 2, for instance, had log EC 50 values of −8.0 and −7.6 (EC 50 : 9 nM and 25 nM), respectively, in the cAMP accumulation assay, but log EC 50 values of −6.3 and −6.3 (EC 50 : 0.5 µM and 0.5 µM), respectively, in the GTPγS binding assay. These differences likely reflect the number of spare receptors that exist for the two different assays used. The cAMP inhibition assay is a more downstream readout that is well known to exhibit signal amplification. GTPγS binding, however, directly measures the initial event (G protein activation) produced in response to receptor activation and is known to exhibit little signal amplification (i.e., a lack of spare receptors relative to the cAMP accumulation assay). It is, however, also possible that these differences may originate from differences in stable versus transient receptor expression systems. Regardless, these data from orthogonal assays confirm that the discovered CB 2 -selective compounds are in fact functionally relevant and stimulate G protein activation as well as inhibition of cAMP accumulation through the inhibition of adenylyl cyclase. Two of the compounds analyzed in further detail (Compounds 1 and 4) were racemic mixes. In the case of these compounds, it is likely that one form is inactive, and the other stimulates the binding and G protein coupling activity; consequently, these parameters are likely better for the pure enantiomeric form that is active. To test this possibility, efforts are underway to synthesize, purify, and separately test the two enantiomeric forms. This next step and pharmacological characterization through SAR of the lead series are important next steps.
In this study, we performed HTS designed to identify both agonists and PAMs of the CB 2 receptor. This HTS used a collaboration deck that was built at BMS and contains 60,000 commercially available compounds. This screen was run at BMS by a Yale graduate student as part of a summer internship program, and follow-up work was performed by researchers at the University of Connecticut. This HTS and follow-up therefore represent an efficient and successful collaboration between industry and academia, a paradigm with growing importance in drug discovery, especially at very early (exploratory) stages.
No CB 2 PAMs were identified in this study, but it does not rule out the possibility that CB 2 PAMs may exist. Because a large number of CB 2 agonists were identified, however, it suggests that CB 2 PAMs are rare. On further characterization of only 4 of 167 agonists identified in this study, we were able to identify compounds with CB 2 selectivity. Because compounds that target the cannabinoid receptors may have analgesic properties, and because of the distinct expression patterns of the CB 2 receptors relative to the CB 1 receptors, the identification of CB 2 -selective compounds carries the potential to be developed into effective pain medications with improved side effect profiles. This study has therefore not only broadened drug discovery efforts aimed at the ECS but also provided critical starting points toward the development of novel CB 2 therapeutics that could lead to improved therapies for pain management and inflammation.
